A nonrandomized, multi-arm phase II trial—results of which were presented by Thorstad et al at the 2024 Multidisciplinary Head and Neck Cancer—assessed the efficacy of two de-escalated adjuvant therapy regimens in patients with surgically resected locally advanced, human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.
